Utility of network integrity methods in therapeutic target identification
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Analysis of the biological gene networks involved in a disease may lead to the identification of therapeutic targets. Such analysis requires exploring network properties, in particular the importance of individual network nodes (i.e., genes). There are many measures that consider the importance of nodes in a network and some may shed light on the biological significance and potential optimality of a gene or set of genes as therapeutic targets. This has been shown to be the case in cancer therapy. A dilemma exists, however, in finding the best therapeutic targets based on network analysis since the optimal targets should be nodes that are highly influential in, but not toxic to, the functioning of the entire network. In addition, cancer therapeutics targeting a single gene often result in relapse since compensatory, feedback and redundancy loops in the network may offset the activity associated with the targeted gene. Thus, multiple genes reflecting parallel functional cascades in a network should be targeted simultaneously, but require the identification of such targets. We propose a methodology that exploits centrality statistics characterizing the importance of nodes within a gene network that is constructed from the gene expression patterns in that network. We consider centrality measures based on both graph theory and spectral graph theory. We also consider the origins of a network topology, and show how different available representations yield different node importance results. We apply our techniques to tumor gene expression data and suggest that the identification of optimal therapeutic targets involving particular genes, pathways and sub-networks based on an analysis of the nodes in that network is possible and can facilitate individualized cancer treatments. The proposed methods also have the potential to identify candidate cancer therapeutic targets that are not thought to be oncogenes but nonetheless play important roles in the functioning of a cancer-related network or pathway.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Network medicine: a network-based approach to human disease
Barabási, A.-L., Gulbahce, N., & Loscalzo, J. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2918 · Cited by 5,034 · cited 1×
“Genes corresponding to high-degree nodes in a PPI network usually have systemwide effects and are involved in multiple pathways including cancer-related pathways (Han et al., 2004; Barabási et al., 2011).”
BackgroundGoh, K.-I., Cusick, M. E., Valle, D., Childs, B., Vidal, M., & Barabási, A.-L. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701361104 · Cited by 3,242
MAP kinase signalling pathways in cancer
Dhillon, A. S., Hagan, S., Rath, O., & Kolch, W. (2007) · Oncogene · doi:10.1038/sj.onc.1210421 · Cited by 2,995 · cited 1×
“It has been well-established that aberrations in MAPK signaling play critical roles in cancer development and progression (Dhillon et al., 2007).”
BackgroundA double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis
Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., Catalano, J. V., Deininger, M., Miller, C., Silver, R. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110557 · Cited by 2,103 · cited 1×
“Interestingly, the FDA-approved drug ruxolitinib is a JAK1 and JAK2 inhibitor, and more JAK inhibitors are in development (Verstovsek et al., 2012).”
BackgroundSmall-molecule inhibitors of protein–protein interactions: progressing towards the dream
Arkin, M. R., & Wells, J. A. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1343 · Cited by 1,705 · cited 1×
“Since it is known that some cancer-related genes and proteins are difficult to target with small molecules, for example the p53 gene, drugs targeting an edge/interaction for which such genes are connected may offer ways of indirectly targeting and influencing those genes (Arkin and Wells, 2004).”
BackgroundThe Epidermal Growth Factor Receptor Pathway: A Model for Targeted Therapy
Scaltriti, M., & Baselga, J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1554 · Cited by 913
WikiPathways: Pathway Editing for the People
Pico, A. R., Kelder, T., van Iersel, M. P., Hanspers, K., Conklin, B. R., & Evelo, C. (2008) · PLoS Biology · doi:10.1371/journal.pbio.0060184 · Cited by 701
Imada, K., & Leonard, W. J. (2000) · Molecular Immunology · doi:10.1016/s0161-5890(00)00018-3 · Cited by 610
JunD Reduces Tumor Angiogenesis by Protecting Cells from Oxidative Stress
Gerald, D., Berra, E., Frapart, Y. M., Chan, D. A., Giaccia, A. J., Mansuy, D., Pouysségur, J., Yaniv, M., & Mechta-Grigoriou, F. (2004) · Cell · doi:10.1016/j.cell.2004.08.025 · Cited by 588
RNA sequencing reveals two major classes of gene expression levels in metazoan cells
Hebenstreit, D., Fang, M., Gu, M., Charoensawan, V., van Oudenaarden, A., & Teichmann, S. A. (2011) · Molecular Systems Biology · doi:10.1038/msb.2011.28 · Cited by 289
Cited by
Drug target prioritization by perturbed gene expression and network information
Isik, Z., Baldow, C., Cannistraci, C. V., & Schroeder, M. (2015) · Scientific Reports · doi:10.1038/srep17417 · Cited by 135
Blizinsky, K. D., Diaz-Castro, B., Forrest, M. P., Schürmann, B., Bach, A. P., Martin-de-Saavedra, M. D., Wang, L., Csernansky, J. G., Duan, J., & Penzes, P. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1607014113 · Cited by 76
“It has been hypothesized that disease phenotypes are a consequence of altered gene pathways or networks, and the optimal therapeutic targets should be nodes that are highly influential to the function of the entire network (24).”
BackgroundFlorian, P., Flechsenhar, K. R., Bartnik, E., Ding‐Pfennigdorff, D., Herrmann, M., Bryce, P. J., & Nestle, F. O. (2020) · Experimental Dermatology · doi:10.1111/exd.13942 · Cited by 20
Drug Target Prioritization for Alzheimer's Disease Using Protein Interaction Network Analysis
Podder, A., Pandit, M., & Narayanan, L. (2018) · OMICS: A Journal of Integrative Biology · doi:10.1089/omi.2018.0131 · Cited by 14
“We have constructed a PPIN for AD by assigning a differential edge weight for each interaction in AlzNet.”
Influential
Metadata
- Authors
- Peng, Q., & Schork, N. J.
- Venue
- Frontiers in Genetics
- Publisher
- Frontiers Media SA
- Published
- 2014
- Volume
- 5
- Pages
- 12-12
- ISSN
- 1664-8021 (ISSN-L)
- OpenAlex
- W2072034250
- Cited by
- 41
- References
- 13
- FWCI
- 1.10
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Utility of network integrity methods in therapeutic target identification. https://app.cochat.ai/papers/10.3389/fgene.2014.00012
- The paper
- Peng, Q., & Schork, N. J. (2014). Utility of network integrity methods in therapeutic target identification. Frontiers in Genetics. https://doi.org/10.3389/fgene.2014.00012
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.